Dr. Parker is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
One MedImmune Way
Gaithersburg, MD 20878Phone+1 202-782-6205
Education & Training
- National Capital ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 1993 - 1994
- National Capital ConsortiumFellowship, Pulmonary Disease and Critical Care Medicine, 1991 - 1993
- National Capital ConsortiumResidency, Internal Medicine, 1988 - 1991
- UniforMed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 1988
Certifications & Licensure
- MD State Medical License 1990 - 2025
Clinical Trials
- A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563). Start of enrollment: 2009 Feb 02
- D2212C00002 J-Phase II Study Start of enrollment: 2014 Jan 01
Publications & Presentations
PubMed
- 31 citationsPlasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiencyAmy D. Shapiro, Charles Nakar, Joseph M. Parker, Gary R. Albert, John E. Moran
Blood. 2018-03-22 - 143 citationsA randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthmaRichard M. Nowak, Joseph M. Parker, Robert Silverman, Brian H. Rowe, Howard A. Smithline
The American Journal of Emergency Medicine. 2015-01-01 - 1 citationsClinical Trial Simulation To Assist In COPD Trial Planning And Design With A Biomarker-Based Diagnostic: When To Pull The Trigger?David L. Gold, Michelle Dawson, Harry Yang, Joseph M. Parker, David Gossage
COPD. 2014-03-25
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: